Supernus Pharmaceuticals Price to Book Ratio 2012-2026 | SUPN
Historical price to book ratio values for Supernus Pharmaceuticals (SUPN) over the last 10 years. The current price to book ratio for Supernus Pharmaceuticals as of September 17, 2026 is 2.33.
| Supernus Pharmaceuticals Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-09-17 | 42.92 | 2.42 | |
| 2026-06-30 | 46.51 | $17.73 | 2.62 |
| 2026-03-31 | 51.69 | $18.55 | 2.79 |
| 2025-12-31 | 49.70 | $18.48 | 2.69 |
| 2025-09-30 | 47.79 | $18.38 | 2.60 |
| 2025-06-30 | 31.52 | $18.96 | 1.66 |
| 2025-03-31 | 32.75 | $18.41 | 1.78 |
| 2024-12-31 | 36.16 | $18.58 | 1.95 |
| 2024-09-30 | 31.18 | $18.24 | 1.71 |
| 2024-06-30 | 26.75 | $17.39 | 1.54 |
| 2024-03-31 | 34.11 | $16.98 | 2.01 |
| 2023-12-31 | 28.94 | $16.84 | 1.72 |
| 2023-09-30 | 27.57 | $16.81 | 1.64 |
| 2023-06-30 | 30.06 | $16.85 | 1.78 |
| 2023-03-31 | 36.23 | $16.81 | 2.15 |
| 2022-12-31 | 35.67 | $16.33 | 2.18 |
| 2022-09-30 | 33.85 | $16.01 | 2.11 |
| 2022-06-30 | 28.92 | $15.80 | 1.83 |
| 2022-03-31 | 32.32 | $15.56 | 2.08 |
| 2021-12-31 | 29.16 | $15.32 | 1.90 |
| 2021-09-30 | 26.67 | $15.33 | 1.74 |
| 2021-06-30 | 30.79 | $14.78 | 2.08 |
| 2021-03-31 | 26.18 | $14.24 | 1.84 |
| 2020-12-31 | 25.16 | $14.09 | 1.79 |
| 2020-09-30 | 20.84 | $13.46 | 1.55 |
| 2020-06-30 | 23.75 | $12.66 | 1.88 |
| 2020-03-31 | 17.99 | $11.68 | 1.54 |
| 2019-12-31 | 23.72 | $11.33 | 2.09 |
| 2019-09-30 | 27.48 | $10.62 | 2.59 |
| 2019-06-30 | 33.09 | $9.97 | 3.32 |
| 2019-03-31 | 35.04 | $9.17 | 3.82 |
| 2018-12-31 | 33.22 | $8.66 | 3.84 |
| 2018-09-30 | 50.35 | $8.07 | 6.24 |
| 2018-06-30 | 59.85 | $7.48 | 8.00 |
| 2018-03-31 | 45.80 | $6.81 | 6.72 |
| 2017-12-31 | 39.85 | $5.21 | 7.65 |
| 2017-09-30 | 40.00 | $4.91 | 8.15 |
| 2017-06-30 | 43.10 | $4.52 | 9.53 |
| 2017-03-31 | 31.30 | $4.10 | 7.63 |
| 2016-12-31 | 25.25 | $3.84 | 6.58 |
| 2016-09-30 | 24.73 | $3.50 | 7.07 |
| 2016-06-30 | 20.37 | $2.23 | 9.15 |
| 2016-03-31 | 15.25 | $1.96 | 7.76 |
| 2015-12-31 | 13.44 | $1.80 | 7.48 |
| 2015-09-30 | 14.03 | $1.61 | 8.69 |
| 2015-06-30 | 16.98 | $1.48 | 11.45 |
| 2015-03-31 | 12.09 | $1.34 | 9.01 |
| 2014-12-31 | 8.30 | $0.95 | 8.76 |
| 2014-09-30 | 8.69 | $0.84 | 10.36 |
| 2014-06-30 | 10.95 | $0.79 | 13.83 |
| 2014-03-31 | 8.94 | $0.69 | 12.96 |
| 2013-12-31 | 7.54 | $0.84 | 9.01 |
| 2013-09-30 | 7.33 | $0.40 | 18.22 |
| 2013-06-30 | 6.43 | $1.16 | 5.54 |
| 2013-03-31 | 5.62 | $1.34 | 4.21 |
| 2012-12-31 | 7.17 | $1.88 | 3.81 |
| 2012-09-30 | 11.55 | $1.01 | 11.47 |
| 2012-06-30 | 9.36 | $1.55 | 6.03 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.409B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |